In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford GlycoSciences PLC

Division of UCB Group
www.ogs.com

Latest From Oxford GlycoSciences PLC

Appointments: EFPIA, Celgene, AcelRx, PureTech Health, Symbiomix, CRISPR Therapeutics and Achaogen

This latest roundup includes EFPIA's appointment of Nathalie Moll to director general, CEO appointments by YposKesi and Symbiomix Therapeutics, as well as various executive appointments by PureTech Health, Arterial Capital Management and Mitra Biotech.

Appointments

CAT Fight with Abbott: The Calculus of Royalty Offsets and Partnering Reputation

The fight between Abbott Laboratories and Cambridge Antibody Technology over two partly overlapping royalty-giveback clauses in their contract on Humira has implications far beyond the money--which itself is not inconsiderable. Abbott could theoretically save itself some $60 million in royalty fees, but it could also win itself a name for playing hardball with its partners, even in the event of a major drug development success.
BioPharmaceutical Strategy

Biotech Executive Recruitment: More Sophisticated Packages Needed

Laurence Monnery MBA, head of the European Life Sciences Practice Group and Tim Cook, Life Sciences Practice consultant at recruitment consultants Egon Zehnder discuss the need for more sophisticated remuneration packages to both attract and retain quality senior managers in European biotechnology.
BioPharmaceutical Europe

Biotechs Beware: Royalty Offset Clauses Can Seriously Damage Your Health

Cambridge Antibody's royalty dispute with partner Abbott over potential blockbuster Humira sends a sobering message to biotechs: beware poorly-constructed royalty offset clauses. The argument won't help Abbott's partnering image, either.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Oxford GlycoSystems
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • UCB Group
  • Senior Management
  • David Ebsworth, CEO
    Denis Mulhall, Dir., Fin. & CFO
    Raj Parekh, CSO
    Peter Zagorin, VP, Mktg.
    Carl Foster, SVP, Bus. Dev.
  • Contact Info
  • Oxford GlycoSciences PLC
    Phone: (44) 1235 208000
    The Forum
    86 Milton Pk.
    Abingdon, OX14 4RY
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register